Home » Newsletters » BioWorld Science

BioWorld Science

July 9, 2018

View Archived Issues

Taking the STING out of autoimmunity

Universiteit Twente presents an ITGA5-binding peptide for pancreatic cancer

New EGFR-TKI to treat T790M-mediated resistant lung cancers

Arsanis describes monoclonal antibody binding Spa and Sbi which protects against S. aureus

ETX-1317 restores the activity of cefpodoxime against beta-lactamase-producing UTI isolates

Homozygous mutation of the TALDO1 gene linked to transladolase deficiency in an adult woman

New missense variant in the FBXW11 gene associated with developmental eye and limb anomalies

Homozygous mutations in SLC10A7 gene linked to skeletal dysplasia

mAChR antagonists/beta2-adrenoceptor agonists patented by Beijing Showby Pharmaceutical

Fatty acid synthase inhibitors synthesized at Cephalon

Orion initiates phase III REFALS study of oral levosimendan for the treatment of ALS

Leo Pharma presents phosphodiesterase PDE4 inhibitors

Hangzhou Innogate Pharma divulges protein kinase inhibitors

Dual GLP-1R/GCGR agonist may help to improve the control of postprandial glucose in type 2 diabetes

Laboratorios del Dr. Esteve discovers dual mu-opioid/sigma1R ligands

New mutant EGFR inhibitors identified at Medshine Discovery

Phase II trial of ZGN-1061 in obesity and diabetes meets all primary objectives at interim analysis

Galapagos outlines phase II trial of GLPG-1205 in IPF

Benitec and Axovant sign licensing agreement for BB-301 and partner on further gene therapy programs

Incyte studies INCB-081776 for advanced solid tumors in phase I

Bayer initiates first-in-human study with BAY-1830839

Tegoprazan approved for the treatment of GERD in Korea

FDA lifts clinical hold on Invossa trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...